Technology
AI-Native Intelligencefor Precision Oncology
Universal Pathway Mapper, TRACE dynamic forecasting, and clinic-ready biomarkers turn multi-modal cancer data into actionable treatment intelligence.
Universal Pathway Mapper
Multi-Modal Data Harmonization
Integrating diverse data types to unlock deeper insights and enable precision-guided care.
TRACE
Trajectory Of Cancer's Evolution
Dynamic Forecasting
Forecasts tumor size, evolution and drug response during multiple lines of treatment for any cancer type. Identifies resistance mechanisms emerging within tumor.
Our First Biomarker Offering
Endorse bx
AI-powered biomarker platform for endocrine therapy response prediction using RNA sequencing from tumor biopsy samples.
Validated across retrospective cohorts and active prospective clinical trials, Endorse bx delivers interpretable outputs through a fully automated biopsy-to-report pipeline.
- Clinical Trial Validated
- Patented
- RNA
- CAP/CLIA Compatible
- Deployed in Clinic
Retrospective Cohorts
Prospective Trials
Interpretable Outputs
Biopsy-to-Report Pipeline
Clinical Validation
Clinical Trials
Studies underway to bring clearer, more personalized treatment decisions to patients and their care teams.
NCT07590583
Open nowENDORSE
ER+ breast cancer · City of Hope
Uses a tumor biopsy to help predict how hormone therapy may work for you. The study is open now with periodic blood draws while full enrollment expands.
NCT07288034
RecruitingIMMUNO-BIOMAP
Non-small cell lung cancer · City of Hope
Follows how lung cancer responds to immunotherapy over time, so your care team can adjust treatment as your tumor changes.
ARPA-H Program
ADAPT
Metastatic breast, lung, and colorectal cancer · National network
A national program that updates treatment as cancer evolves, using biomarkers and real-time data across leading cancer centers.
Our Science
Supporting Publications
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers
2025
Blocking cancer-fibroblast mutualism inhibits proliferation of endocrine therapy resistant breast cancer
2025
Cell facilitation promotes growth and survival under drug pressure in breast cancer
2023
ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers
2022
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
2021